In Thursday’s Wall Street session, CryoPort Inc (NASDAQ:CYRX) shares traded at $5.55, down -1.16% from the previous session.
CYRX stock price is now -8.85% away from the 50-day moving average and -25.15% away from the 200-day moving average. The market capitalization of the company currently stands at $276.76M.
With the price target maintained at $10, UBS recently Upgraded its rating from Neutral to Buy for CryoPort Inc (NASDAQ: CYRX). On December 19, 2024, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $11, while ‘Jefferies’ rates the stock as ‘Hold’
In other news, Sawicki Mark W, Chief Scientific Officer sold 1,349 shares of the company’s stock on Mar 24 ’25. The stock was sold for $9,364 at an average price of $6.94. Upon completion of the transaction, the Chief Scientific Officer now directly owns 84,087 shares in the company, valued at $0.47 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 24 ’25, Chief Financial Officer STEFANOVICH ROBERT sold 1,070 shares of the business’s stock. A total of $7,428 was realized by selling the stock at an average price of $6.94. This leaves the insider owning 190,349 shares of the company worth $1.06 million. A total of 3.68% of the company’s stock is owned by insiders.
During the past 12 months, CryoPort Inc has had a low of $4.58 and a high of $17.41. As of last week, the company has a debt-to-equity ratio of 0.62, a current ratio of 5.29, and a quick ratio of 4.94. The fifty day moving average price for CYRX is $6.0836 and a two-hundred day moving average price translates $7.4087 for the stock.
The latest earnings results from CryoPort Inc (NASDAQ: CYRX) was released for 2024-12-31. The net profit margin was -53.75% and return on equity was -25.76% for CYRX. The company reported revenue of $59.53 million for the quarter, compared to $57.26 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.97 percent.
